‘Adverse events’“Man, that is a lot of adverse events," said Tony Moody, a doctor and researcher at the Duke Human Vaccine Institute.
He said it would be “unusual" for a vaccine to have this rate of side effects.On the plus side, Moody said that the antibody levels produced were “really encouraging." The neutralizing antibody levels in the trial produced were equivalent to the upper half of what’s seen in patients who get infected with the virus and recover, according to the results published Tuesday in the New England Journal of Medicine.Moderna’s shares gained about 16% in US pre-market trading Wednesday.
The stock has more than tripled in value this year on hopes that the company’s vaccine will gain rapid approval. The vaccine will move.
Read more on livemint.com